LiverLearning®: 2019 Webinar: HCC Staging and Treatments

This webinar will cover Barcelona Clinic Liver Cancer (BCLC) staging in hepatocellular carcinoma. Attendees will also receive an overview of curative options of surgical resection, liver transplant, and ablative techniques and noncurative options of TACE, TARE, SBRT, and systemic chemotherapy. We will utilize a live webinar format that will be recorded for on-demand viewing on Liver Learning ® .Vicki Shah Vicki Shah PA-C, MMS received a Bachelor’s of Science in Biochemistry with minor in Mathematics from California State University, Long Beach.

Monoacylglycerol Lipase Inhibition Protects From Liver Injury in Mouse Models of Sclerosing Cholangitis

Matteo Tardelli, Francesca V. Bruschi, Claudia D. Fuchs, Thierry Claudel, Nicole Auer, Victoria Kunczer, Maximilian Baumgartner, Onne A.H.O. Ronda, Henk Jan Verkade, Tatjana Stojakovic, Hubert Scharnagl, Aida Habib, Robert Zimmermann, Sophie Lotersztajn, Michael Trauner – 10 September 2019

Hepatocyte Stress Increases Expression of Yes‐Associated Protein and Transcriptional Coactivator With PDZ‐Binding Motif in Hepatocytes to Promote Parenchymal Inflammation and Fibrosis

Meghan Mooring, Brendan H. Fowl, Shelly Z.C. Lum, Ye Liu, Kangning Yao, Samir Softic, Rory Kirchner, Aaron Bernstein, Aatur D. Singhi, Daniel G. Jay, C. Ronald Kahn, Fernando D. Camargo, Dean Yimlamai – 10 September 2019

Incidence of and Risk Factors for Hepatic Encephalopathy in a Population‐Based Cohort of Americans With Cirrhosis

Elliot B. Tapper, James B. Henderson, Neehar D. Parikh, George N. Ioannou, Anna S. Lok – 6 September 2019 – Hepatic encephalopathy (HE) is a devastating complication of cirrhosis. Data are limited regarding the incidence of and risk factors for HE among contemporary patients in the context of the shifting epidemiology of cirrhosis. We examined a 20% random sample of U.S. Medicare enrollees with cirrhosis and Part D prescription coverage from 2008 to 2014. We modelled incident HE using demographic, clinical, and pharmacologic data.

Thrombocytopenia and Procedural Prophylaxis in the Era of Thrombopoietin Receptor Agonists

Kathy M. Nilles, Stephen H. Caldwell, Steven L. Flamm – 4 September 2019 – Thrombocytopenia is common in patients with advanced liver disease. These patients frequently require invasive diagnostic or therapeutic procedures in the setting of thrombocytopenia. A common platelet goal before such procedures is ≥50,000/μL, but target levels vary by provider and the procedure. Platelet transfusion has disadvantages, including safety and cost.

Subscribe to